Goldman Sachs Maintains Neutral on GoodRx Holdings, Raises Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Eric Sheridan has maintained a Neutral rating on GoodRx Holdings (NASDAQ:GDRX) and increased the price target from $6.5 to $7.5.
March 01, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on GoodRx Holdings but raises the price target from $6.5 to $7.5.
The increase in price target by Goldman Sachs suggests a positive outlook on the stock's potential, likely leading to a short-term positive impact on its price. However, the Neutral rating indicates that there are still some reservations or uncertainties surrounding the company's performance, which might temper the stock's upward movement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100